| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | myricetin | CTRPv2 | pan-cancer | AAC | -0.0072 | 0.9 |
| mRNA | tivantinib | CTRPv2 | pan-cancer | AAC | 0.009 | 0.9 |
| mRNA | BRD-K80183349 | CTRPv2 | pan-cancer | AAC | -0.0061 | 0.9 |
| mRNA | A-770041 | GDSC1000 | pan-cancer | AAC | 0.01 | 0.9 |
| mRNA | quizartinib | CTRPv2 | pan-cancer | AAC | -0.0067 | 0.9 |
| mRNA | BRD-K34099515 | CTRPv2 | pan-cancer | AAC | 0.014 | 0.9 |
| mRNA | Crizotinib | GDSC1000 | pan-cancer | AAC | -0.01 | 0.9 |
| mRNA | Nilotinib | GDSC1000 | pan-cancer | AAC | -0.0064 | 0.9 |
| mRNA | AT-406 | CTRPv2 | pan-cancer | AAC | -0.0086 | 0.9 |
| mRNA | Rapamycin | gCSI | pan-cancer | AAC | -0.0092 | 0.9 |